Study of ALXN1840 Versus Standard of Care in Pediatric Participants With Wilson Disease

Study Identifier:
ALXN1840-WD-302
ClinicalTrials.gov Identifier:
NCT05047523
EudraCT Identifier:
2021-001015-82
EU CT ID:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Other

Available Documents

ProtocolStatistical Analysis Plan

Study Details

Medical Condition
  • Unmapped
Study Drug
  • Drug: ALXN1840
  • Drug: Standard of Care
Date
Sep 2021 - Jun 2023
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 3 - 17 Years
Requirements Information
Sex
Female & Male
Age
3 - 17 Years

Study Details

Medical Condition
  • Unmapped
Study Drug
  • Drug: ALXN1840
  • Drug: Standard of Care
Date
Sep 2021 - Jun 2023
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 3 - 17 Years years
Requirements Information

Protocol Summary

This study is being conducted to evaluate the efficacy, safety, pharmacokinetics (PK), and pharmacodynamics of ALXN1840 versus standard of care in pediatric participants with Wilson disease (WD).

Trial Locations

Location
Status
Location
Research Site
Parkville, Australia, VIC 3052
Status
N/A
Location
Research Site
South Brisbane, Australia, 4101
Status
N/A
Location
Research Site
Lille, France, 59037
Status
N/A
Location
Research Site
Toulouse, France, 31059
Status
N/A
Location
Research Site
Hannover, Germany, 30625
Status
N/A
Location
Research Site
Tübingen, Germany, 72076
Status
N/A
Go to page